REPUBLIC OF KENYA

MINISTRY OF HEALTH

THE PHARMACY AND POISONS BOARD

Ensuring safety, quality and efficacy of medicines

PRESS STATEMENT ON RECALL OF PANADOL BABY AND INFANT SUSPENSION

The Pharmacy and Poisons Board (PPB) through the Ministry of Health is aware of the recall of Panadol Baby and infant Suspension by GlaxoSmithKline (GSK). This was necessitated by identification of discrepancy in dosing table during a routine review by GSK .

PPB would like to assure the public that the recall is due to the **labelling discrepancy** and not the **quality of the medicine**.

The following measures are in place to ensure public safety;

- PPB has since engaged with the GSK to have the products recalled from all the outlets.
- Due to this engagement, GSK agreed to recall the product from all outlets at their own cost following the laid down procedures.
- GSK sought the authority of the regulatory authority, Pharmacy and Poisons Board to change the dosing tables . PPB reviewed the safety profile and authority was granted.
- The recall has been iniatiated to remove all the batches manufactured before December 2014 which had discrepancy.

The Pharmacy and Poisons Board wishes to assure the public that there should be no panic as the safety risk of the discrepancy has been reviewed and found to be very insignificant.

As the recall proceeds, we advise the public to use other registered brands of baby and infant Paracetamol suspension available in the market .

The Pharmacy and Poisons Board is the Drug Regulatory Authority established under the Pharmacy and Poisons Act, Cap 244 of the Laws of Kenya to protect the health of the public by ensuring quality, safety and efficacy of medical products and technologies in Kenya.

DR. KIPKERICH KOSKEI, OGW
REGISTRAR